Details for New Drug Application (NDA): 062759
✉ Email this page to a colleague
NDA 062759 describes ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL, which is a drug marketed by Barr and is included in one NDA. Additional details are available on the ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL profile page.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
The generic ingredient in ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL is erythromycin ethylsuccinate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin ethylsuccinate; sulfisoxazole acetyl profile page.
Summary for 062759
| Tradename: | ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL |
| Applicant: | Barr |
| Ingredient: | erythromycin ethylsuccinate; sulfisoxazole acetyl |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | GRANULE;ORAL | Strength | EQ 200MG BASE/5ML;EQ 600MG BASE/5ML | ||||
| Approval Date: | May 20, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
